BioPlus Acquisition Corp.
BIOSDelisted Oct 6, 2023- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001856653
BioPlus Acquisition Corp. was delisted on Oct 6, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 30 institutions reported holding it in 13F filings for Q3 2023, worth $135.2M in total; no superinvestor held it.
Q2 2023 vs. Q1 2023
How the institutions holding BioPlus Acquisition Corp. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 61 | 1 | 32 | −28 |
| Shares | 22.1M | 250.0K | 12.4M | −9.44M (−43.2%) |
| Value | $230.7M | $2.61M | $132.1M | −$96.0M (−42.1%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held BioPlus Acquisition Corp. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mizuho Securities USA LLC | 1,014,334 | $10.7M | 0.36% |
| Quarry LP | 455,000 | $4.85M | 3.14% |
| Spartan Fund Management Inc. | 160,316 | $1.71M | 0.83% |
| Prelude Capital Management, LLC | 150,000 | $1.60M | 0.13% |
| Atlas Merchant Capital LLC | 50,000 | $532.5K | 0.11% |
| UBS Group AG | 1,828 | $19.5K | 0.00% |
Sold out (34)
Institutions that held BioPlus Acquisition Corp. at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (1)
Institutions that held BioPlus Acquisition Corp. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Davidson Kempner Partners | 250,000 | $2.61M |